Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the pricing of an underwritten public offering of 8,181,819 shares of its common stock at a public offering price of $5.50 per share for gross proceeds of approximately $45 million, before deducting underwriting discounts and commissions and other offer